A Phase 4 interventional study of Enavogliflozin and Dapagliflozin or Empagliflozin in Diabetes Mellitus, Type 2, Cardiovascular Diseases and Kidney Diseases, sponsored by Yonsei University. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2024-10-15.
Sponsored by Yonsei University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing enavogliflozin in Diabetes Mellitus, Type 2 — 7 open to participants now, 8 under way, 4 of them phase 3. Enavogliflozin · Diabetes Mellitus, Type 2.
Among the 15 studies testing enavogliflozin in Diabetes Mellitus, Type 2, this one has the largest planned enrollment, is one of 2 that started in 2024, is one of 3 in phase 4, and was the 13th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →7 of the 15 studies testing enavogliflozin in Diabetes Mellitus, Type 2 are open now, in 1 country. Recruiting first, the newest first:
Korea University Anam Hospital · Sites in Korea, Republic of
Ages 20–79
Seoul National University Bundang Hospital · Sites in Korea, Republic of
Ages 20–80
Daewoong Pharmaceutical Co. LTD. · Sites in Korea, Republic of
Ages 19–80 · Healthy volunteers
Daewoong Pharmaceutical Co. LTD. · Sites in Korea, Republic of
Ages 19–80
Daewoong Pharmaceutical Co. LTD. · Sites in Korea, Republic of
Ages 18–80
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 2 started in 2024.
This study's planned enrollment of 2,862 is above the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 140 across the 15 interventional studies. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 15 have an industry lead sponsor. The 4 most frequent:
Yonsei University is the lead sponsor of 1,421 studies on the registry; 241 are open to participants now.
20 studies in Diabetes Mellitus, Type 2 by Yonsei University: 5 open now, 6 under way, none of them phase 3. Of 11 finished, 0 (0%) have results posted.
Among the 20 studies in Diabetes Mellitus, Type 2 by Yonsei University, this one has the largest planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2024, is one of 10 in phase 4, and was the 18th registered.
Yonsei University’s Diabetes Mellitus, Type 2 studies by the year they started, since 2007.
2 of the studies testing enavogliflozin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07619833Phase 3Daewoong Pharmaceutical Co. LTD.To Evaluate the Efficacy and Safety of Initial Combination Therapy With DWP16001 and DWC202518 Compared to DWP16001 Monotherapy and DWC202518 Monotherapy in Patients With Type 2 Diabetes Mellitus | 2027-11 |
| NCT06399835Seoul National University Bundang HospitalEnavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies testing enavogliflozin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Yonsei University’s 20 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The novel sodium-glucose cotransporter-2 (SGLT2) inhibitor, enavogliflozin, effectively reduces glycated hemoglobin (HbA1c) levels and body weight without increasing the risk of serious adverse events. However, its long-term clinical benefits concerning cardiovascular and renal outcomes have yet to be thoroughly studied. This study is an investigator-initiated, multicenter, randomized, pragmatic, open-label, active-controlled, non-inferiority trial. Eligible participants are adults aged 19 or older with type 2 diabetes who have a history of, or are at risk for, cardiovascular disease. A total of 2,862 participants will be randomly assigned to receive either enavogliflozin or other SGLT2 inhibitors with proven cardiorenal benefits, such as dapagliflozin or empagliflozin. The primary endpoint is the time to the first occurrence of a composite of major adverse cardiovascular and renal events. This trial aims to determine whether enavogliflozin is non-inferior to dapagliflozin or empagliflozin in terms of cardiorenal outcomes in patients with type 2 diabetes and cardiovascular risk factors. It will also clarify role of enavogliflozin in preventing vascular complications in this patient population.
The ENVELOP study aims to assess cardiorenal outcomes following enavogliflozin administration compared with dapagliflozin or empagliflozin in Korean patients with type 2 diabetes, representing the first large-scale SGLT2 inhibitor outcome study targeting this population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will take Enavogliflozin according to the investigator's judgment.
Drug: Enavogliflozin
Subjects will take Dapagliflozin or Empagliflozin according to the investigator's judgment.
Drug: Dapagliflozin or Empagliflozin
The dosage and administration method are determined according to the investigator's judgment, considering the drug's approval requirements and the medical condition of the study participants.
The dosage and administration method are determined according to the investigator's judgment, considering the drug's approval requirements and the medical condition of the study participants.
Time from randomization to first onset of cardiorenal composite outcome event
Major adverse cardiovascular events include nonfatal myocardial infarction (MI), nonfatal stroke, and hospitalization for unstable angina, hospitalization for heart failure, coronary or peripheral revascularization, and death from any cause. Renal events include a sustained decline in estimated glomerular filtration rate (GFR) calculated by means of the Chronic Kidney Disease Epidemiology Collaboration equation of ≥40% from baseline to \<60 mL/min/1.73m2, onset of end-stage kidney disease (dialysis for ≥28 days, kidney transplantation, or an estimated GFR of \<15 mL/min/1.73m2), development of macroalbuminuria, and death from renal causes.
Time frame: 6 months, 12 months, 24 months, 36 months and 48 month
Time from randomization to the first onset of 3-point MACE and proportion of the patients
Time to first event of a composite of key major adverse cardiovascular events (non-fatal MI, non-fatal stroke, and death from cardiovascular causes)
Time frame: 6 months, 12 months, 24 months, 36 months and 48 months
death from any cause
Time to death from any cause
Time frame: 6 months, 12 months, 24 months, 36 months and 48 months
death from cardiovascular causes
Time to death from cardiovascular cause
Time frame: 6 months, 12 months, 24 months, 36 months and 48 months
hospitalization due to unstable angina
Time to first event of hospitalization due to unstable angina
Time frame: 6 months, 12 months, 24 months, 36 months and 48 months
hospitalization due to heart failure
Time to first event of hospitalization due to heart failure
Time frame: 6 months, 12 months, 24 months, 36 months and 48 months
coronary or peripheral revascularization
Time to first event of coronary or peripheral revascularization
Time frame: 6 months, 12 months, 24 months, 36 months and 48 months
major renal events
Time to first event of a composite of major kidney events
Time frame: 6 months, 12 months, 24 months, 36 months and 48 months
progression of macroalbuminuria
Time to development of macroalbuminuria
Time frame: 6 months, 12 months, 24 months, 36 months and 48 months
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2024 (actual). Primary completion is estimated for Sep 2029, 68 months after the start.
Of 320 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 68 months is above that.
Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enavogliflozin